Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits.
about
Saperconazole therapy of murine disseminated candidiasis: efficacy and interactions with amphotericin BOverview of medically important antifungal azole derivativesIn vitro and in vivo efficacy of the triazole TAK-187 against Cryptococcus neoformansIn vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformansCryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.The gene encoding phosphoribosylaminoimidazole carboxylase (ADE2) is essential for growth of Cryptococcus neoformans in cerebrospinal fluid.Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologiesPharmacokinetics of fluconazole in cerebrospinal fluid and serum of rabbits: validation of an animal model used to measure drug concentrations in cerebrospinal fluid.Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain.Comparison of fluconazole and SDZ89-485 for therapy of experimental murine coccidioidomycosis.Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis.In vitro and in vivo activities of Sch 39304, fluconazole, and amphotericin B against Histoplasma capsulatum.Treatment of murine coccidioidal meningitis with SCH39304Azole antifungal agents: emphasis on new triazoles.Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitisComparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata, and Candida krusei.In vitro models for studying toxicity of antifungal agentsPenetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis.Fluconazole in the treatment of Candida-associated denture stomatitis.Antifungal pharmacokinetics and pharmacodynamicsCorrelation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1.Targeted gene replacement demonstrates that myristoyl-CoA: protein N-myristoyltransferase is essential for viability of Cryptococcus neoformans.Comparison of fluconazole and amphotericin B for treatment of disseminated candidiasis and endophthalmitis in rabbits.CNS pharmacokinetics of antifungal agents.Fluconazole. Review and situation among antifungal drugs in the treatment of opportunistic mycoses of human immuno-deficiency virus infections.Tissue penetration of antifungal agents.New antifungal agents for the systemic mycoses.In vitro and in vivo evaluation of antifungal agents.Current concepts in cryptococcosis.Transcriptomic analysis of Ustilago maydis infecting Arabidopsis reveals important aspects of the fungus pathogenic mechanismsTreatment of systemic fungal infections: recent progress and current problems.Comparison of fluconazole and itraconazole in a rabbit model of coccidioidal meningitis.Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans.Reflections on the approach to treatment of a mycologic disaster.Potential use of a simplified method for determination of itraconazole levels in plasma and esophageal tissue by using high-performance liquid chromatography.Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice.Activities of fluconazole (UK 49,858) and ketoconazole against ketoconazole-susceptible and -resistant Candida albicans.Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304.Treatment of experimental disseminated candidiasis with cilofungin.Fluconazole (UK-49,858) treatment of candidiasis in normal and diabetic rats
P2860
Q24616032-04750257-EE33-487D-94B3-DB8A25E96D67Q24617248-C27106A7-1DDF-4433-85E3-3A86917C1838Q28369024-EFDEAC29-A87D-4E76-A12C-1F303CC7FB37Q28379195-FBBB1C60-FC96-4846-9EDD-E252C677835BQ30424017-DA3258C8-C5B3-4AF8-9E0D-5F4FD6EF8EA8Q33612121-5EAF1A7F-14DF-4D90-A776-D1D85081D128Q33677651-9A36BFC1-3A9A-4B6D-90AF-2EC0E11522DFQ33758961-53EDDBA7-1909-4138-AF08-B3EEB500ACFBQ35116163-F86BBFBE-3E2B-499F-BA20-B85FDCFD12B9Q35245267-3F228031-D4D8-4826-8982-7C1E7551A827Q35250532-82BA1402-E4DE-4849-95B8-D92066C6B862Q35251766-32242CFC-F719-42E1-B068-686CF86209BEQ35252722-63BF69EA-2D50-4909-AC5C-FF186A5D7903Q35287663-C0B557D2-47BA-4B06-999B-4D796113BCB8Q35295703-0BF51DFA-1E95-4018-913D-0AB7590BAAB5Q35347298-1A591524-9793-4186-965C-97980D7F4AABQ35447528-1F01530E-75E8-4555-8705-822F6BF41D03Q35535337-C0C50281-9326-4E83-9974-2186A4E7068EQ35565993-FB141C66-1134-48EA-93F2-F383898E9CC3Q35663841-EFD28B35-F51C-4F2D-84F8-B9B4EDDD3A48Q35900199-A360E983-D131-472A-90E9-3103A9792AB1Q35953363-9CCED8B2-3783-47C3-A5B4-319F2A87504AQ36752863-F2704654-0875-4047-A535-001E95025C41Q36909333-B9A2A5AF-D887-48CA-AC72-8989CFF88B03Q37245969-840557BF-FFD2-4256-91AE-B8B23D1F33C3Q37544911-22BC5807-7B59-4ACD-8DFD-AAB16E374D7AQ37876231-9EE04A22-0EEB-4B6D-B2C5-C1BCB62F6B81Q38223673-4D69F312-3C9A-4222-BBDB-3D2A92920D42Q38229538-BFC4236B-6F27-451A-94AD-D4F55496232CQ39097618-21367E09-01CF-4CA5-975A-B796592EC7E2Q39277897-D95452E4-67CF-47DC-AD31-3B5F1628D0A3Q39474027-171C02E7-9563-41A9-9099-561EDF1C859CQ39557816-E4DD5BD0-825C-40BB-B540-42F21DA1EC57Q39767419-5E10DD60-8948-4709-A17F-78A600391D96Q39779411-F5E3538E-DF0C-4143-9153-D66C2F715FAEQ39814888-BCE59236-25EB-4266-B2EC-8E10BAD0B6DBQ39817645-E15FBC97-C672-4B22-9217-C6A74A87CB44Q39820104-DA7EFBEF-BA00-4C6F-969B-E957194F5126Q39820154-C365C07E-57AA-4038-8648-416E73AC0074Q39833032-49132CAD-951E-44B3-9C06-A8A8B6382FBD
P2860
Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年学术文章
@wuu
1986年学术文章
@zh-cn
1986年学术文章
@zh-hans
1986年学术文章
@zh-my
1986年学术文章
@zh-sg
1986年學術文章
@yue
1986年學術文章
@zh
1986年學術文章
@zh-hant
name
Comparison of itraconazole and ...... ida pyelonephritis in rabbits.
@en
Comparison of itraconazole and ...... ida pyelonephritis in rabbits.
@nl
type
label
Comparison of itraconazole and ...... ida pyelonephritis in rabbits.
@en
Comparison of itraconazole and ...... ida pyelonephritis in rabbits.
@nl
prefLabel
Comparison of itraconazole and ...... ida pyelonephritis in rabbits.
@en
Comparison of itraconazole and ...... ida pyelonephritis in rabbits.
@nl
P2093
P2860
P356
P1476
Comparison of itraconazole and ...... ida pyelonephritis in rabbits.
@en
P2093
P2860
P304
P356
10.1128/AAC.29.4.579
P407
P577
1986-04-01T00:00:00Z